Testing effectiveness (Phase 2)Active Not RecruitingNCT06508749What this trial is testingThe Tatelo Plus StudyWho this might be right forHIVHIV Infections National Institute of Allergy and Infectious Diseases (NIAID) 41
Testing effectiveness (Phase 2)Study completedNCT00002127What this trial is testingA Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting SyndromeWho this might be right forHIV InfectionsHIV Wasting Syndrome Celgene Corporation 75
Testing effectiveness (Phase 2)Study completedNCT03497676What this trial is testingMore Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and AdolescentsWho this might be right forHIV Infections National Institute of Allergy and Infectious Diseases (NIAID) 168
Testing effectiveness (Phase 2)Study completedNCT01504841What this trial is testingEvaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and ChildrenWho this might be right forHIV Infections National Institute of Allergy and Infectious Diseases (NIAID) 26
Testing effectiveness (Phase 2)Study completedNCT01008813What this trial is testingClinical Trial to Evaluate the Immunogenicity and Safety of an Adjuvanted A(H1N1)v Influenza Vaccine and a Non-adjuvanted A(H1N1)v Influenza Vaccine in HIV-infected Patients (ANRS 151 Hifluvac)Who this might be right forHIV Infections French National Agency for Research on AIDS and Viral Hepatitis 306
Testing effectiveness (Phase 2)Study completedNCT00225303What this trial is testingTMC125-C227: A Phase II Randomized, Active-Controlled, Open Label Trial to Investigate the Efficacy and Tolerability of TMC125 in HIV-1 Infected Subjects, Who Are PI-Naive and With Documented Genotypic Evidence of NNRTI Resistance From Previous NNRTI UseWho this might be right forHIV Infection Tibotec Pharmaceuticals, Ireland 116
Post-approval studies (Phase 4)Study completedNCT03290391What this trial is testingLinking Infectious and Narcology Care-Part IIWho this might be right forHIV InfectionDrug Use Boston Medical Center 225
Testing effectiveness (Phase 2)Study completedNCT00002210What this trial is testingDelavirdine Mesylate in Combination With Other Anti-HIV Drugs in HIV-Infected Children and BabiesWho this might be right forHIV Infections Pharmacia and Upjohn 24
Testing effectiveness (Phase 2)Study completedNCT00007332What this trial is testingSafety and Immune Response Study of the Vaccine ALVAC vCP1452 Alone or in Combination With AIDSVAX B/BWho this might be right forHIV Infections National Institute of Allergy and Infectious Diseases (NIAID) 330
Testing effectiveness (Phase 2)Study completedNCT00917891What this trial is testingAn Expanded Safety Study of Dapivirine Gel 4759 in AfricaWho this might be right forHIV InfectionsAcquired Immunodeficiency Syndrome International Partnership for Microbicides, Inc. 280
Testing effectiveness (Phase 2)Study completedNCT00024024What this trial is testingBMS-275291 in Treating Patients With HIV-Related Kaposi's SarcomaWho this might be right forSarcoma National Cancer Institute (NCI) 59
Not applicableStudy completedNCT01258582What this trial is testingTwo Approaches to Routine HIV Testing in a Hospital Emergency DepartmentWho this might be right forHIV Infections Massachusetts General Hospital 1,651
Testing effectiveness (Phase 2)Study completedNCT01816490What this trial is testingTHISTLE - The HIV-HCV Silibinin TrialWho this might be right forHIVHepatitis C University of Zurich 20
Testing effectiveness (Phase 2)UnknownNCT04404049What this trial is testingThe HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 PatientsWho this might be right forHIV-1-infection UBP Greater China (Shanghai) Co., Ltd 39
Early research (Phase 1)Study completedNCT00000755What this trial is testingA Phase I/II Trial of Vaccine Therapy of HIV-1 Infected Individuals With 50-500 CD4 Cells/mm3Who this might be right forHIV Infections National Institute of Allergy and Infectious Diseases (NIAID) 168
Testing effectiveness (Phase 2)Study completedNCT00109590What this trial is testingReducing the Incidence of Nevirapine Resistance Mutations in Pregnant HIV Infected Women Who Receive Anti-HIV Drugs Prior to and After Giving BirthWho this might be right forHIV Infections National Institute of Allergy and Infectious Diseases (NIAID) 175
Testing effectiveness (Phase 2)Looking for participantsNCT04941274What this trial is testingAbemaciclib in Patients With HIV-associated and HIV-negative Kaposi SarcomaWho this might be right forKaposi Sarcoma National Cancer Institute (NCI) 111
Testing effectiveness (Phase 2)WithdrawnNCT00723918What this trial is testingCombination of an Investigational Cannabinoid and Methadone for HIV-associated NeuropathyWho this might be right forHIV-associated NeuropathyPolyneuropathy Washington University School of Medicine
Testing effectiveness (Phase 2)Study completedNCT00046033What this trial is testingComparing Standard-Dose Versus Adjusted-Dose Lopinavir/Ritonavir Therapy in HIV-Infected Persons With Drug ResistanceWho this might be right forHIV Infections National Institute of Allergy and Infectious Diseases (NIAID) 118
Testing effectiveness (Phase 2)Looking for participantsNCT05470491What this trial is testingTrial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...Who this might be right forHIVHematologic Malignancies National Cancer Institute (NCI) 265